Tiziana Life Sciences (NASDAQ:TLSA) announced on October 16, 2026, that the final patient began dosing in its Phase 2 intranasal foralumab trial for early or mild Alzheimer’s disease.
Ladder Capital (NYSE:LADR) reported third-quarter 2026 GAAP income before taxes of $67.3 million and diluted earnings of $0.53 per share, supported by investment activity and an asset sale.
CLPS (NASDAQ:CLPS) reported fiscal 2026 revenue of $172.2 million, up 4.7%, despite a widening second-half net loss of $13.2 million.
Biomerica (NASDAQ:BMRA) reported a fiscal first-quarter 2027 net loss of $1.232 million, or $0.37 per share, as revenue declined 8% to $1.265 million.
NeOnc Technologies Holdings (NASDAQ:NTHI) reported early clinical improvements in one three-year-old brain tumor patient receiving investigational intranasal NEO100 through its Compassionate Care program in Abu Dhabi.
Private Bancorp of America (NASDAQ:PBAM) reported unaudited third-quarter 2026 net income of $11.4 million, with diluted earnings of $1.97 per share, reflecting year-over-year growth despite a sequential decline.
Aduro Clean Technologies (NASDAQ:ADUR) reported C$1.202 million in quarterly income for the period ended August 31, 2026, compared with a C$6.325 million loss a year earlier.
NN (NASDAQ:NNBR) launched its fourth product line of 2026, establishing a Cable Assembly and Wire Harness business with production centered in Ciudad Juárez, Mexico.
Zenta Group (NASDAQ:ZTG) said its ZentoAI subsidiary signed a memorandum of understanding to acquire control of a profitable mainland Chinese AI and digital technology provider.
Organon (NYSE:OGN) announced interim six-year Phase 3 results for its licensed hormone-free MIUDELLA contraceptive device, reporting a cumulative Pearl Index of 0.93.
GET YOUR GRAFA EDGE NOW
We'll switch on a 30-day Edge trial as a welcome gift
-640x360.webp&w=3840&q=75)